ArticleBMC infectious diseases2025
Association between vaccination status and clinical characteristics among young adults infected with COVID-19.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo explore the association between Vaccination Status and Clinical Characteristics Among Young Adults Infected With COVID-19.
methodsWe conducted a cross-sectional Survey among young adults aged 16-35 years in Tianjin, China. Our analysis focused on COVID-19 infection rates, risk factors, demographic characteristics, and clinical symptoms.
resultsWe collected 738 valid questionnaires between December 20 to 23, 2022, achieving a response rate of 98.27%. Among the 412 infected participants, 33.25% were male and 66.75% were female, with a marginal significant difference (P = 0.054). The distribution of infected participants across various age groups, as well as the presence or absence of co-residents, showed a significant difference between the infected and uninfected cohorts (P = 0.003 and P < 0.001, respectively). Compared with participants who received two or less vaccine dose, participants who had received three or more doses of vaccine had a significantly lower incidence of headache (0-2 vs. > = 3 doses: 80.43% and 69.38%, P = 0.038), olfactory reduction or loss (0-2 vs. > = 3 doses: 22.83% and 14.06%, P = 0.043). Compared with the time since vaccination of 7-12 months, those vaccinated with less than 6 months or more than 12 months exhibited a higher incidence of fatigue (< 6 vs. 7-12 vs. > 12 months: 75.41%, 63.13% and 77.61%, P = 0.009) but a lower incidence of vomiting (< 6 vs. 7-12 vs. > 12 months: 8.20%, 17.51% and 8.21%, P = 0.020).
conclusionOur study found that young adults who received three or more doses of the COVID-19 vaccine had a lower incidence of symptoms such as headache and olfactory reduction. These findings underscore the importance of vaccination in mitigating the severity of COVID-19 symptoms and provide valuable insights for future public health strategies and vaccine policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.